5LSG
PPARgamma complex with the betulinic acid
Summary for 5LSG
Entry DOI | 10.2210/pdb5lsg/pdb |
Descriptor | Peroxisome proliferator-activated receptor gamma, Betulinic Acid (3 entities in total) |
Functional Keywords | antagonist, complex, transcription factor, nuclear receptor, signaling protein |
Biological source | Homo sapiens (Human) |
Cellular location | Nucleus: P37231 |
Total number of polymer chains | 2 |
Total formula weight | 69620.50 |
Authors | Pochetti, G.,Montanari, R.,Capelli, D.,Loiodice, F.,Laghezza, A.,Calleri, E.,Paiardini, A. (deposition date: 2016-08-26, release date: 2017-08-09, Last modification date: 2024-01-17) |
Primary citation | Brusotti, G.,Montanari, R.,Capelli, D.,Cattaneo, G.,Laghezza, A.,Tortorella, P.,Loiodice, F.,Peiretti, F.,Bonardo, B.,Paiardini, A.,Calleri, E.,Pochetti, G. Betulinic acid is a PPAR gamma antagonist that improves glucose uptake, promotes osteogenesis and inhibits adipogenesis. Sci Rep, 7:5777-5777, 2017 Cited by PubMed Abstract: PPAR antagonists are ligands that bind their receptor with high affinity without transactivation activity. Recently, they have been demonstrated to maintain insulin-sensitizing and antidiabetic properties, and they serve as an alternative treatment for metabolic diseases. In this work, an affinity-based bioassay was found to be effective for selecting PPAR ligands from the dried extract of an African plant (Diospyros bipindensis). Among the ligands, we identified betulinic acid (BA), a compound already known for its anti-inflammatory, anti-tumour and antidiabetic properties, as a PPARγ and PPARα antagonist. Cell differentiation assays showed that BA inhibits adipogenesis and promotes osteogenesis; either down-regulates or does not affect the expression of a series of adipogenic markers; and up-regulates the expression of osteogenic markers. Moreover, BA increases basal glucose uptake in 3T3-L1 adipocytes. The crystal structure of the complex of BA with PPARγ sheds light, at the molecular level, on the mechanism by which BA antagonizes PPARγ, and indicates a unique binding mode of this antagonist type. The results of this study show that the natural compound BA could be an interesting and safe candidate for the treatment of type 2 diabetes and bone diseases. PubMed: 28720829DOI: 10.1038/s41598-017-05666-6 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2 Å) |
Structure validation
Download full validation report
